AOD-9604 Compounding Pharmacy: How to Read a Certificate of Analysis

What AOD-9604 Is and Why Sourcing Rigor Matters

AOD-9604 is a synthetic fragment of human growth hormone spanning amino acid residues 176 to 191. Early research suggested it may influence lipolysis without the insulin-resistance effects seen with full-length GH, though no large randomized controlled trial has established clinical efficacy in humans for weight loss. Because the FDA has never approved AOD-9604 as a drug product, every vial dispensed in the United States comes from a compounding pharmacy operating under either Section 503A or Section 503B of the Federal Food, Drug, and Cosmetic Act. [1]

The 503A vs. 503B Distinction

A 503A pharmacy compounds for individual patients on a prescription-by-prescription basis. A 503B outsourcing facility can produce larger batches without patient-specific prescriptions but must register with the FDA and meet current Good Manufacturing Practice (cGMP) standards. The practical difference for a buyer is significant: 503B facilities face FDA inspections, mandatory adverse-event reporting, and batch-release testing that is functionally equivalent to pharmaceutical manufacturing. [2]

Most AOD-9604 dispensed through telehealth channels comes from 503A pharmacies. That is not inherently dangerous, but it places more of the quality-assurance burden on the prescribing clinician and the patient. Reading the COA yourself is therefore not optional.

Why the COA Is Your Primary Safety Document

A COA is the manufacturer's own attestation that a specific lot meets predetermined specifications. For compounded peptides, a credible COA is generated by an independent, ISO 17025-accredited analytical laboratory, not by the compounding pharmacy itself. The FDA's guidance on compounding quality, as well as a series of warning letters issued to peptide compounders between 2020 and 2024, highlights that self-generated COAs with no third-party verification are a consistent pattern in substandard operations. [3]

The Regulatory Framework Behind Every AOD-9604 COA

Compounding pharmacies in the United States operate under a layered set of federal and state requirements that directly determine what a COA must contain. Understanding that framework lets you judge whether a pharmacy is cutting corners.

USP <797> and Sterile Compounding Standards

USP <797> sets the environmental monitoring, beyond-use dating, and personnel training requirements for sterile preparations. A revised chapter took effect November 1, 2023, tightening Category 1 and Category 2 beyond-use dates and adding stricter requirements for sterility testing of batches released before results are available. [4] An AOD-9604 injectable vial prepared under USP <797> must have: a controlled cleanroom environment (ISO 5 or better at the point of fill), documented personnel competency assessments, and a COA that references the specific beyond-use date tied to the compounding category.

USP <795> and Oral or Topical Forms

Some clinicians prescribe AOD-9604 as a sublingual troche or topical cream. Those non-sterile forms fall under USP <795>. The bioavailability of non-sterile AOD-9604 remains poorly characterized in peer-reviewed literature, but the compounding requirements are less stringent than for injectables. A COA for a troche will typically show assay (potency) and uniformity of dosage units rather than sterility or endotoxin. [5]

FDA DSCSA and Track-and-Trace

The Drug Supply Chain Security Act (DSCSA) requires pharmacies to be able to trace a product back through the supply chain. For compounded peptides, this means the pharmacy should be able to provide the API (active pharmaceutical ingredient) supplier's COA on request, showing the raw peptide's purity before compounding. If a pharmacy cannot produce the API-level COA, the final-product COA is unverifiable. [6]

State Board Oversight and PCAB Accreditation

State boards of pharmacy set the enforcement floor. Texas, California, and Florida, for example, have their own sterile-compounding regulations that exceed or supplement USP <797> in certain respects. PCAB accreditation through the Accreditation Commission for Health Care (ACHC) is a voluntary but meaningful signal: accredited pharmacies undergo on-site inspections every three years and must maintain documented quality systems. Choosing a PCAB-accredited pharmacy does not guarantee a perfect product, but it reduces the probability of catastrophic failures substantially. [7]

Reading an AOD-9604 COA Line by Line

A standard COA from a qualified analytical lab contains at minimum six sections. Below is how to interpret each one for an AOD-9604 injectable preparation.

1. Identity: Confirming You Have AOD-9604

The identity section should show one or more of the following: liquid chromatography-mass spectrometry (LC-MS), high-resolution mass spectrometry (HRMS), or amino acid analysis. The expected molecular formula for AOD-9604 (the 16-amino-acid C-terminal fragment) is C78H123N23O23S2, with a molecular weight of approximately 1,817.1 Da. [8]

A COA that lists identity as "peptide confirmed by HPLC retention time" alone is insufficient. HPLC retention time only confirms the compound elutes at the right time under those specific conditions. Mass spectrometry confirms the actual molecular identity. Reject any COA that lacks an MS-based identity test.

2. Purity: HPLC Area-Under-the-Curve

HPLC purity is expressed as a percentage of the total peak area attributed to the target peptide. For injectable use, the acceptable specification should be not less than 98.0% by area. Anything below 95% is categorically unacceptable for human use. The impurity profile matters too: individual unknown impurities should be <0.5% each, and total impurities should be <2.0%. [9]

The HPLC method should be described. A reversed-phase C18 column with a gradient elution using acetonitrile/water with trifluoroacetic acid is the standard approach for this class of peptides. If the COA simply says "HPLC: 98.5%" without any method description, ask the pharmacy for the full analytical method validation report.

3. Potency: Assay vs. Label Claim

Potency is reported as the measured content relative to the label claim, expressed as a percentage. Acceptable limits under USP compounding standards are generally 90% to 110% of label claim. A vial labeled 5 mg/mL should contain between 4.5 and 5.5 mg/mL of AOD-9604.

Watch for pharmacies that conflate purity with potency. They measure different things. A product can be 99% pure but only 80% potent if the compounding process lost material, or if the API stock was lower than declared.

4. Sterility: USP <71>

Injectable AOD-9604 must pass USP <71> sterility testing. The test incubates samples in fluid thioglycollate medium (for anaerobes) and soybean-casein digest medium (for aerobes and fungi) for 14 days. A passing result means no growth in either medium. [10]

Two caveats matter here. First, sterility testing has a finite sensitivity limit. A batch can pass and still contain a very low level of contamination. This is why good manufacturing practice controls (cleanroom environment, aseptic technique) are the primary defense, with sterility testing as a confirmatory check. Second, many 503A pharmacies use parametric release rather than end-product sterility testing for short-beyond-use-date products. Ask which method was used.

5. Endotoxin: USP <85> Bacterial Endotoxins Test

Endotoxin testing uses the Limulus amebocyte lysate (LAL) assay. For parenteral products administered subcutaneously, the general limit is 2.0 EU/mL or less, though the precise limit depends on the route, dose, and weight-based calculation per USP <85>. [11]

Endotoxins cause fever, hypotension, and systemic inflammation. They are not removed by standard sterilization filtration. A COA that omits endotoxin data for an injectable product is missing one of the most clinically significant safety parameters.

6. Residual Solvents and Appearance

High-quality COAs will also include residual solvent testing (particularly for acetonitrile and trifluoroacetic acid used in HPLC purification of the API), a visual appearance check (clear, colorless, particulate-free), and pH. Residual TFA can cause injection-site reactions at high concentrations. Class 2 residual solvents like acetonitrile have ICH Q3C limits of 410 ppm. [12]

Red Flags That Should Stop a Purchase

The following framework summarizes the most common COA deficiencies identified in FDA warning letters and published pharmaceutical quality assessments of compounded peptides. Use it as a binary checklist before accepting a lot of AOD-9604 from any pharmacy.

| COA Element | Acceptable | Reject If | |---|---|---| | Identity method | LC-MS or HRMS confirming MW | HPLC retention time only | | Purity | 98.0% or above | Below 95% | | Potency | 90-110% of label | Outside this range | | Sterility | USP <71> pass, 14-day incubation | Missing, or self-reported | | Endotoxin | <2.0 EU/mL, LAL method | Missing for injectables | | Lab accreditation | ISO 17025 third-party lab | In-house pharmacy lab only | | Lot number on COA | Present and matches vial label | Missing or generic | | Beyond-use date | Matches USP <797> category | Not stated |

An FDA analysis of 503A pharmacy compliance deficiencies published in agency inspection data found that failures in sterility testing documentation and environmental monitoring were among the most frequently cited issues in compounding pharmacies that received warning letters between 2018 and 2023. [13]

Is AOD-9604 Legal to Buy?

AOD-9604 occupies a legally specific position. The FDA has not approved it as a drug. It is not on the FDA's 503A or 503B "bulk drug substance" lists that explicitly permit compounding. As of the publication date of this article, the FDA's List of Bulk Drug Substances That May Be Used in Compounding Under Section 503A does not include AOD-9604 by name, which means pharmacies compounding it do so under a legal gray area that the FDA has not yet formally resolved. [14]

Prescription Requirement

Regardless of that gray area, obtaining compounded AOD-9604 without a valid prescription from a licensed prescriber is illegal for a patient and creates significant liability for the pharmacy. Research-use-only (RUO) suppliers that sell AOD-9604 online without a prescription are not operating as pharmacies and are not subject to pharmacy compounding standards. Products from those sources carry no clinical safety protections.

FDA Enforcement History

The FDA issued multiple warning letters to peptide compounders between 2020 and 2024, citing failures in sterility, labeling, and quality systems. Several letters specifically mentioned GH fragment peptides. The pattern in those letters was consistent: pharmacies with no PCAB accreditation, self-generated COAs, and no environmental monitoring data. [3]

The "Research Peptide" Loophole Is Not a Loophole

Websites selling AOD-9604 labeled "for research use only, not for human use" are not exempt from FDA enforcement when the context makes clear the product is intended for human administration. The FDA's position, articulated in its 2022 guidance on compounding, is that intent governs regulation, not the label alone. [15]

How to Choose a Pharmacy for AOD-9604

Choosing a compounding pharmacy for AOD-9604 should follow the same due-diligence process a hospital pharmacy director would apply. These steps are concrete and verifiable.

Step 1: Confirm 503A or 503B Registration

Ask for the pharmacy's state license number and verify it with the relevant state board of pharmacy. For 503B facilities, verify registration directly with the FDA's drug shortage and outsourcing facility database. A pharmacy that cannot provide a verifiable license number should be disqualified immediately.

Step 2: Request the Third-Party Lab COA Before Purchase

A reputable pharmacy will provide the COA for the specific lot you are receiving before you commit to the purchase, not after. The lab name on the COA should be independently verifiable. Search the lab's name with "ISO 17025 accreditation" to confirm certification. The NVLAP (National Voluntary Laboratory Accreditation Program) and A2LA (American Association for Laboratory Accreditation) maintain searchable public databases of accredited labs.

Step 3: Verify PCAB Accreditation

Search the ACHC website directly at achc.org for PCAB-accredited pharmacies. Do not rely on a pharmacy's self-declaration of accreditation. The ACHC database is publicly accessible and updated regularly. [7]

Step 4: Check for Prior FDA Warning Letters

The FDA's database of warning letters is searchable by recipient name and date. Search for the pharmacy name specifically, not just the category. A warning letter does not mean the pharmacy is still non-compliant, but it requires follow-up: ask the pharmacy what corrective actions were taken and whether an FDA re-inspection confirmed those corrections. [13]

Step 5: Evaluate Prescriber Involvement

A clinical-grade AOD-9604 prescription should come after a full clinical assessment. The prescribing clinician should review labs (including IGF-1, metabolic panel, and body composition data where available), document the indication, and monitor for adverse effects. Telehealth platforms that issue AOD-9604 prescriptions after a two-minute intake form with no lab review are not meeting the standard of care expected for compounded peptide therapy.

Is Research-Grade AOD-9604 Safe for Human Use?

Research-grade AOD-9604 sold by non-pharmacy vendors is not subject to any of the USP or FDA compounding standards described in this article. It is not safe for human use. The term "research grade" is not a quality standard; it is a marketing category that exists outside pharmaceutical regulation entirely.

What the Clinical Evidence Actually Shows

The most detailed clinical data on AOD-9604 comes from a series of studies conducted by Metabolic Pharmaceuticals in the early 2000s. A Phase 2 randomized trial (N=300) tested oral AOD-9604 at doses of 1 mg and 5 mg daily for 12 weeks and found no statistically significant weight loss compared with placebo. [16] A subsequent 24-week Phase 2b trial in obese adults showed similarly modest results. The compound never advanced to Phase 3 trials for obesity. That does not make it worthless, but it does mean the evidentiary base for clinical use is limited.

Risk Profile at Compounded Doses

Subcutaneous AOD-9604 at doses of 250 to 500 mcg daily is the range most commonly prescribed at telehealth platforms. No published RCT has established the safety profile of injected AOD-9604 at those doses in humans. The absence of published serious adverse events in the literature should not be read as confirmed safety; it may reflect underreporting and the relative novelty of peptide compounding at this scale. The American Association of Clinical Endocrinologists (AACE) position on compounded GH-related peptides cautions against use outside of IRB-approved clinical trials, noting that the risk-benefit ratio cannot be quantified without controlled trial data. [17]

Practical Checklist: Before Your First AOD-9604 Vial

1. Obtain a prescription from a clinician who has reviewed your labs and documented the clinical rationale.
2. Request the COA for the specific lot before the pharmacy ships.
3. Confirm the COA comes from an ISO 17025-accredited third-party laboratory.
4. Check that HPLC purity is 98.0% or above, potency is 90-110% of label, endotoxin is <2.0 EU/mL, and sterility testing passed per USP <71>.
5. Verify the lot number on the COA matches the lot number on the vial when it arrives.
6. Confirm the pharmacy is PCAB-accredited or 503B-registered.
7. Store the vial per the labeled storage condition (typically 2-8°C, refrigerated, protected from light) and discard after the stated beyond-use date.

The National Institute of Standards and Technology defines a beyond-use date as the date after which a compounded preparation may not be used, and USP <797> Category 2 sterile preparations tested and released have beyond-use dates of up to 45 days refrigerated or 6 months frozen. [18] Verify which category applies to the vial you receive.